2 mg perampanel + 4 mg perampanel + placebo comparator

Phase 3Completed
1 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Parkinson's Disease

Conditions

Parkinson's Disease

Trial Timeline

Aug 1, 2006 → Jan 1, 2008

About 2 mg perampanel + 4 mg perampanel + placebo comparator

2 mg perampanel + 4 mg perampanel + placebo comparator is a phase 3 stage product being developed by Eisai for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00368108. Target conditions include Parkinson's Disease.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson's Disease were approved

Approved (20) Terminated (3) Active (0)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00368108Phase 3Completed

Competing Products

20 competing products in Parkinson's Disease

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
19
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
22
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
35
E2007EisaiPhase 3
32
ARICEPTEisaiPhase 3
40
PerampanelEisaiPhase 3
32
GPI 1485EisaiPhase 2
35
E2007EisaiPhase 3
40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
40
perampanel + placeboEisaiPhase 2
27
Lemborexant + placeboEisaiApproved
50
Placebo + E2007 + E2007EisaiPhase 3
32
E2007 + E2007 + E2007EisaiPhase 2
35
E2007EisaiPhase 2
35
E2007EisaiPhase 2
27
E2007EisaiPhase 2
27
Istradefylline (KW-6002)Kyowa KirinPhase 2
35
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
40
Istradefylline (KW-6002)Kyowa KirinPhase 3
40
PerampanelEisaiPhase 2
27